《睡眠專業人士雜誌》
星期四, 七月 23, 2026
Panthera Dental announced Panthera DUO, an ordering option that provides two appliances of the same design ordered together for the same patient. With choice of two different designs- Panthera Classic or Panthera X3– Panthera DUO helps dental practices maintain continuity of care and support adherence for patients who cannot afford […]
Airway Management proudly announces a historic milestone with the FDA clearance of Nylon flexTAP®, the world’s first digitally printed single-point midline oral appliance device for sleep apnea. This revolutionary device redefines patient care by combining cutting-edge patented Vertex Technology® with unparalleled comfort and efficacy, now FDA cleared for mild to moderate obstructive […]
Eisai Co., Ltd. announced today that the results from a Phase Ib clinical trial (NCT06462404) of its in-house developed novel selective orexin 2 receptor agonist E2086 have been presented at the World Sleep 2025 congress, held in Singapore from 九月 5 to 10. These data demonstrate that once-daily dosing of […]
If your dentist or sleep physician has recommended oral appliance therapy to treat your obstructive sleep apnea (OSA), you might be wondering how it works. This guide walks you through the basics so you’ll know what to expect and how to get the best results. What Is a Mandibular Advancement […]
Takeda will present data from two global Phase 3 double-blind, placebo-controlled studies of oveporexton (TAK-861)1, a potential first-in-class investigational oral orexin receptor 2 (OX2R)-selective agonist in narcolepsy type 1 (NT1), during multiple oral presentations at the World Sleep 2025 Congress in Singapore. Both the FirstLight (TAK-861-3001) and RadiantLight (TAK-861-3002) […]
Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, and XWPharma Ltd. (“XWPharma”) together announced today that Avadel has entered into an exclusive global license agreement with XWPharma to develop and commercialize valiloxybate, a GABAB receptor agonist, for all indications, including the treatment of sleep disorders, such […]
Millions of people worldwide who suffer with chronic insomnia are all too familiar with its profound impact on cognitive function, mood, and overall health and well-being. Many of these patients have success with first-line treatments like cognitive behavioral therapy (CBT) and pharmacological interventions, but relief remains elusive for many with […]
EnsoData has announced a collaboration with Takeda to jointly develop and validate AI-based polysomnography (PSG) algorithms to support more accurate and scalable diagnosis of narcolepsy type 1 (NT1). Upon successful validation and regulatory clearance, EnsoData will pursue the clinical availability and release of AI algorithms to enable future access, use, […]
ProSomnus Sleep Technologies announced significant progress on strategic programs. The key feature is the successful FDA registration of the company’s HWO2 buccal mucosal wellness oximeter. The ProSomnus HWO2 Device enables patients to monitor their nightly health and wellness during sleep, specifically, blood oxygen saturation, pulse rate and overall use time, […]
Apnimed, Inc. has announced positive topline results from its second pivotal Phase 3 clinical trial of Apnimed’s lead candidate AD109 (aroxybutynin 2.5mg/atomoxetine 75mg). LunAIRo was a 12-month study that evaluated the efficacy and safety of AD109 in adults with mild, moderate and severe OSA, across a wide range of weight […]
